J Requena, A B Alvarez-Palomo, M Codina-Pascual, R Delgado-Morales, S Moran, M Esteller, M Sal, M Juan-Otero, A Boronat Barado, A Consiglio, O Addeleccia Bogle, E Wolvertang, D Ovchinnikov, I Alvarez, D Jaraquemada, J Mezquita-Pla, R Oliva, M J Edel
When considering the clinical applications of autologous cell replacement therapy of human iPSC-derived cells there is a clear need to better understand what the immune response will be before we embark on extensive clinical trials to treat or model human disease. We performed a detailed assessment comparing human fibroblast cell lines (termed F1) reprogrammed into human iPSC and subsequently differentiated back to fibroblast cells (termed F2) or other human iPSC-derived cells including neural stem cells made from either retroviral, episomal or synthetic mRNA cell reprogramming methods...
January 3, 2019: Stem Cells